Curiosis
Seoul, KR · Public · 1 known investors
Curiosis is a biotech company focusing on bio-pharmaceutical supply chain components and materials. The company operates in the medical device and biotechnology sector in South Korea.
Also known as Curiosis Inc. · Curiosis, Inc. · 큐리오시스
Founders & leadership
Investors · 1
Company profile
researched Aug 2026Curiosis (큐리오시스) is a Seoul, South Korea-based company that develops integrated instruments and solutions for life science laboratories, positioning itself as a bio "소부장" (materials, parts and equipment) supplier focused on laboratory automation. Its work spans cell-based applications, with instruments intended to improve the accuracy and efficiency of cell analysis and to reduce researcher hands-on time [0][3].
The business is organized around two lines: laboratory automation (life science automation) and in vitro diagnostic medical devices. The diagnostics line includes digital pathology systems such as the MSP320 scanner, which converts tissue slides into high-resolution digital images for diagnosis, analysis and sharing. Product families referenced by the company include the Celloger live-cell imaging line (including Celloger Stack-H for large-scale biopharmaceutical production) and CPX, an automated colony picking system [0]. Third-party directory listings categorize the company's product portfolio under cell analyzers [3].
Business model
Curiosis designs and manufactures laboratory instruments and in vitro diagnostic medical devices that it sells to research and clinical users, and it also manufactures equipment for other companies on an ODM basis — for example, an ODM supply contract with Levity valued at about 11 billion Korean won with expanded supply volumes, and a plant expansion in Yongin described as a response to broader global ODM cooperation [0].
Traction
The company reports regulatory clearances and certifications for its products, including Korean medical device product and manufacturing approval for its automated digital pathology scanner (2023) and NEP certification for the CPX colony picker (2026), alongside commercial ODM supply agreements and partnerships with Korean biotech firms [0][1].
Latest developments
Recent company announcements include a memorandum of understanding with Gradiant Bioconvergence to enter the organoid-based drug evaluation market (2026-08), a decision to issue one bonus share per share in a 100% bonus issue (2026-06), NEP certification for the CPX automated colony picking system (2026-05), an approximately 11 billion won ODM supply contract with Levity (2026-05), an MOU with Medipost on cell therapy production automation and QC system upgrades (2026-05), patent registration for core Celloger Stack-H technology (2026-05), the unveiling of Celloger Stack-H for large-scale biopharmaceutical production at AACR (2026-04), and expansion of the Yongin plant (2026-03) [0].
▸Full profile — market position, technology, go-to-market, geography
Market position
Curiosis is a South Korean supplier of laboratory automation and cell analysis instrumentation whose live-cell imaging equipment was designated a 2023 Next-Generation World-Class Product, and which has received R&D 100 Awards in the United States and multiple design awards (iF, Red Dot, IDEA) as well as intellectual-property management awards from the Korean Intellectual Property Office [0][1].
Technology
The company describes a set of in-house technology platforms underpinning its instruments: CurioAMD (automation-optimized structural design and hypercasting), CurioBoard (proprietary electrical/electronic and single-board-computer-based instrument development plus in-house imaging sensor technology), CurioMoptics (opto-mechatronics, proprietary optical transport design and automation-optimized cell analysis), CurioLogics (embedded hardware/software, biomedical image processing and algorithm development), Filterless Filter (NEP/NET-certified cell separation, automated cell concentration and biochip design) and CurioFactory (ultra-precision mold design, 10-micrometer-class precision injection molding and biochip packaging). Its expert team is described as combining biophysics and electronic engineering [0][3].
Go-to-market
Life science researchers and laboratories performing cell-based work, and clinical and diagnostic users of digital pathology and in vitro diagnostic devices; the company also serves corporate partners as an ODM manufacturer of laboratory equipment [0][3].
Geography
Headquartered in Seoul, South Korea (Teheran-ro 38-gil), with a manufacturing plant in Yongin that has been expanded; the company also markets internationally, presenting products at the AACR meeting in the United States [0][3].
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 13
launches, deals, and filingsCuriosis signed a memorandum of understanding with Gradiant Bioconvergence to enter the organoid drug evaluation market.
The company decided on a 100% bonus issue, allocating one new share per existing share.
Curiosis obtained New Excellent Product (NEP) certification for its CPX automated colony picking system.
Curiosis announced an ODM supply contract with Levity valued at approximately 11 billion Korean won, with expanded supply quantities.
Curiosis and Medipost signed an MOU covering automation of cell therapy manufacturing and advancement of QC systems.
Curiosis presented Celloger Stack-H, aimed at large-scale biopharmaceutical production, at the AACR meeting in the US.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Curiosiscuriosis.co.kr · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Curiosis do?
- Korean bio materials-parts-equipment company building lab automation systems, cell analysis instruments and digital pathology scanners.
- Who are Curiosis's investors?
- Curiosis's investors include Kiwoom Investment.
- Where is Curiosis headquartered?
- Curiosis is headquartered in Seoul, KR.